1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Ebrahim S Delpassand: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 Administering Lutetium-177-PSMA-617 (PLUVICTO) - Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis | Phase 2 | Recruiting | Ebrahim S Delpassand | 30 | 2025-05-23 | 2025-05-15 |
| 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms 177Lu-DOTATATE - Neuroendocrine Tumors | Phase 2 | Completed | Ebrahim S Delpassand | 143 | 2010-10-27 | 2023-03-20 |
Neuroendocrine Tumors (1) · Prostatic Neoplasms (1)
Pluvicto (1) · lutetium Lu 177 dotatate (1)
United States (2)